

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1 (Cancelled).

2 (Currently Amended): A method of screening for an endometrial cancer disease in a subject; ~~the method~~ comprising:

(a) detecting the level or amount of human chaperonin 10 in a biological sample obtained from the subject, wherein the human chaperonin 10 is the native-sequence polypeptide of human chaperonin 10 or a fragment, precursor, modified form, chimeric form, complex, or derivative thereof, and wherein the biological sample is blood or an endometrial tissue extract; and

(b) comparing the level or amount in step (a) with a level or amount of human chaperonin 10 in a control,

wherein a significant difference in the level or amount of human chaperonin 10 in the biological sample, relative to the corresponding level or amount in the control, is indicative of endometrial cancer disease.

3 (Currently Amended): ~~A~~ The method as claimed in of claim 2, further comprising:

(a) contacting the biological sample obtained from ~~a~~ the subject with at least one binding agent that specifically binds to human chaperonin 10; ~~and~~

(b) detecting in the biological sample the level or amount of human chaperonin 10 that binds to the binding agent, ~~relative to a pre-determined standard or cut-off value;~~ and ~~therefrom determining the presence or absence of the endometrial disease in the subject~~



(c) comparing the level or the amount of bound human chaperonin 10 with the level or amount in a control,

wherein a significant difference in the level or amount of bound human chaperonin 10 in the biological sample, relative to the corresponding level or amount in the control, is indicative of endometrial cancer.

4 (Currently Amended): ~~A The method as claimed in~~ of claim 3, wherein the binding agent is an antibody.

5 (Cancelled).

6 (Currently Amended): ~~A The method as claimed in~~ of claim 3, wherein the level or amount of human chaperonin 10 in the biological sample is significantly higher than the ~~pre-determined standard or cut-off value~~ level or amount of human chaperonin 10 in the control, and is indicative of endometrial cancer.

7 (Cancelled).

8 (Currently Amended): ~~A The method as claimed in~~ of claim 2, wherein the biological sample is serum ~~obtained from a tissue, extract, cell culture, cell lysate, lavage fluid, or physiological fluid.~~

9 (Currently Amended): ~~A The method as claimed in~~ of claim 2 8, wherein the ~~biological sample~~ endometrial tissue extract is obtained from a an endometrial ~~tumor tissue.~~

10-18 (Cancelled).

19 (Currently Amended): A method for monitoring the progression of endometrial cancer in a subject, ~~the method~~ comprising: (a) detecting in a biological sample obtained from the subject, at a first time point, a level or amount of human chaperonin 10, wherein the biological sample is



blood or an endometrial tissue extract, and wherein the human chaperonin 10 is the native-sequence polypeptide of human chaperonin 10 or a fragment, precursor, modified form, chimeric form, complex, or derivative thereof; (b) repeating step (a) at a subsequent point in time; and (c) comparing the levels or amounts of human chaperonin 10 detected in steps (a) and (b), and thereby monitoring the progression of endometrial cancer.

20 (Currently Amended): A method for determining in a subject whether endometrial cancer has metastasized or is likely to metastasize in the future, comprising comparing: (a) a level or amount of human chaperonin 10; in a biological sample obtained from the subject, wherein the human chaperonin 10 is the native-sequence polypeptide of human chaperonin 10 or a fragment, precursor, modified form, chimeric form, complex, or derivative thereof, and wherein the biological sample is blood or an endometrial tissue extract; and (b) the normal level or amount or non-metastatic level or amount of human chaperonin 10 in a control, wherein a significant difference between the level or amount of human chaperonin 10 in the biological sample and the normal level or amount or non-metastatic level or amount of human chaperonin 10 in the control is an indication that the endometrial cancer has metastasized.

21 (Currently Amended): A method for assessing the aggressiveness or indolence of endometrial cancer in a subject, comprising comparing: (a) a level of expression of human chaperonin 10 in a biological sample obtained from the subject, wherein the human chaperonin 10 is the native-sequence polypeptide of human chaperonin 10 or a fragment, precursor, modified form, chimeric form, complex, or derivative thereof, and wherein the biological sample is blood or an endometrial tissue extract; and (b) a normal level of expression of human chaperonin 10 in a control, wherein a significant difference between the level of expression in the biological sample and the normal level of expression in the control is an indication that the cancer is aggressive or indolent.

22-49 (Cancelled).